Thymidine phosphorylase, dihydropyrimidine dehydrogenase and thymidylate synthase mRNA expression in primary colorectal tumors—correlation to tumor histopathology and clinical follow-up (original) (raw)

References

1. Ragnhammar P, Hafström L, Nygren P, Glimenius B (2001) A systematic overview of chemotherapy effects in colorectal cancer. Acta Oncol 40:282–308
   Article PubMed Google Scholar
2. Iqbal S, Lenz HJ (2001) Determinants of prognosis and response to therapy in colorectal cancer. Curr Oncol Rep 3:102–108
   PubMed Google Scholar
3. Kumar SK, Goldberg RM (2001) Adjuvant chemotherapy for colon cancer. Curr Oncol Rep 3:94–101
   PubMed Google Scholar
4. Diasio RB, Johnson MR (2000) The role of pharmacogenetics and pharmacogenomics in cancer chemotherapy with 5-fluorouracil. Pharmacology 61:199–203
   Article PubMed Google Scholar
5. Furukawa T, Yoshimura A, Sumizawa T, Haraguchi M, Akiyama S, Fukui K, Ishizawa M, Yamada Y (1992) Angiogenic factor. Nature 356:668
   Article PubMed Google Scholar
6. Sumizawa T, Furukawa T, Haraguchi M, Yoshimura A, Takeyasu A, Ishizawa M, Yamada Y, Akiyama S (1993) Thymidine phosphorylase activity associated with platelet-derived endothelial cell growth factor. J Biochem (Tokyo) 114:9–14
   Google Scholar
7. Takebayashi Y, Akiyama S, Akiba S, Yamada K, Miyadera K, Sumizawa T, Yamada Y, Murata F, Aikou T (1996) Clinicopathologic and prognostic significance of an angiogenic factor, thymidine phosphorylase, in human colorectal carcinoma. J Natl Cancer Inst 88:1110–1117
   PubMed Google Scholar
8. Griffiths L, Stratford IJ (1997) Platelet-derived endothelial cell growth factor thymidine phosphorylase in tumour growth and response to therapy. Br J Cancer 76:689–693
   PubMed Google Scholar
9. Metzger R, Danenberg K, Leichman CG, Salonga D, Schwartz EL, Wadler S, Lenz HJ, Groshen S, Leichman L, Danenberg PV (1998) High basal level gene expression of thymidine phosphorylase (platelet-derived endothelial cell growth factor) in colorectal tumors is associated with nonresponse to 5-fluorouracil. Clin Cancer Res 4:2371–2376
   PubMed Google Scholar
10. Salonga D, Danenberg KD, Johnson M, Metzger R, Groshen S, Tsao-Wei DD, Lenz HJ, Leichman CG, Leiuchman L, Diasio RB, Danenberg PV (2000) Colorectal tumors responding to 5-fluorouracil have low gene expression levels of dihydropyrimidine dehydrogenase, thymidylate synthase, and thymidine phosphorylase. Clin Cancer Res 6:1322–1327
    PubMed Google Scholar
11. Takenoue T, Nagawa H, Matsuda K, Fujii S, Nita EM, Hatano K, Kitayama J, Tssuruo T, Muto T (2000) Relation between thymidylate synthase expression and survival in colon carcinoma, and determination of appropriate application of 5-fluorouracil by immunohistochemical method. Ann Surg Oncol 7:193–198
    PubMed Google Scholar
12. Araki Y, Isomoto H, Shirouzu K (2001) Dihydropyrimidine dehydrogenase activity and thymidylate synthase level are associated with response to 5-fluorouracil in human colorectal cancer. Kurume Med J 48:93–98
    PubMed Google Scholar
13. Edler D, Glimelius B, Hallström M, Jakobsen A, Johnston PG, Magnusson I, Ragnhammar P, Blomgren H (2002) Thymidylate synthase expression in colorectal cancer: a prognostic and predictive marker of benefit from adjuvant fluorouracil-based chemotherapy. J Clin Oncol 20:1721–1728
    Article PubMed Google Scholar
14. Kornmann M, Link KH, Galuba I, Ott K, Schwabe W, Häusler P, Scholz P, Sträter J, Polat S, Leibl B, Kettner E, Schlichting C, Baumann W, Schramm H, Hecker U, Ridwelski K, Vogt JH, Zerbian KU, Schütze G, Kreuser ED, Behnke D, Beger HG (2002) Association of time to recurrence with thymidylate synthase and dihydropyrimidine dehydrogenase mRNA expression in stage II and III colorectal cancer. J Gastrointest Surg 6:331–337
    Article PubMed Google Scholar
15. Kornmann M, Schwabe W, Sander S, Kron M, Sträter J, Polat S, Kettner E, Weiser HF, Baumann W, Schramm H, Häusler P, Ott K, Behnke D, Staib L, Beger HG, Link KH (2003) Thymidylate synthase and dihydropyrimidine dehydrogenase mRNA expression levels: predictors for survival in colorectal cancer patients receiving adjuvant 5-fluorouracil. Clin Cancer Res 9:4116–4124
    PubMed Google Scholar
16. Popat S, Matakidou A, Houlston RS (2004) Thymidylate synthase expression and prognosis in colorectal cancer: a systematic review and meta-analysis. J Clin Oncol 22:529–536
    Article PubMed Google Scholar
17. Ichikawa W, Uetake H, Shirota Y, Yamada H, Nishi N, Nihei Z, Sugihara K, Hirayama R (2003) Combination of dihydropyrimidine dehydrogenase and thymidylate synthase gene expressions in primary tumors as predictive parameters for the efficacy of fluoropyrimidine-based chemotherapy for metastatic colorectal cancer. Clin Cancer Res 9:786–791
    PubMed Google Scholar
18. Copur S, Aiba K, Drake JC, Allegra CJ, Chu E (1995) Thymidylate synthase gene amplification in human colon cancer cell lines resistant to 5-fluorouracil. Biochem Pharmacol 49:1419–1426
    Article PubMed Google Scholar
19. Wang W, Marsh S, Cassidy J, McLeod HL (2001) Pharmacogenomic dissection of resistance to thymidylate synthase inhibitors. Cancer Res 61:5505–5510
    PubMed Google Scholar
20. Johnston PG, Lenz HJ, Leichman CG, Danenberg KD, Allegra CJ, Danenberg PV, Leichman L (1995) Thymidylate synthase gene and protein expression correlate and are associated with response to 5-fluorouracil in human colorectal and gastric tumors. Cancer Res 55:1407–1412
    PubMed Google Scholar
21. Bathe OF, Franceschi D, Livingstone AS, Moffat FL, Tian E, Ardalan B (1999) Increased thymidylate synthase gene expression in liver metastases from colorectal carcinoma: implications for chemotherapeutic options and survival. Cancer J Sci Am 5:34–40
    PubMed Google Scholar
22. Wei X, McLeod HL, McMurrough J, Gonzalez FJ, Fernandez-Salguero P (1996) Molecular basis of the human dihydropyrimidine dehydrogenase deficiency and 5-fluorouracil toxicity. J Clin Invest 98:610–615
    PubMed Google Scholar
23. Johnson MR, Hageboutros A, Wang K, High L, Smith JB, Diasio RB (1999) Life-threatening toxicity in a dihydropyrimidine dehydrogenase-deficient patient after treatment with topical 5-fluorouracil. Clin Cancer Res 5:2006–2011
    PubMed Google Scholar
24. Marsh S, McKay JA, Cassidy J, McLeod HL (2001) Polymorphism in the thymidylate synthase promoter enhancer region in colorectal cancer. Int J Oncol 19:383–386
    PubMed Google Scholar
25. Iacopetta B, Grieu F, Joseph D, Elsaleh H (2001) A polymorphism in the enhancer region of the thymidylate synthase promoter influences the survival of colorectal cancer patients treated with 5-fluorouracil. Br J Cancer 85:827–830
    Article PubMed Google Scholar
26. Van Kuilenburg AB, Haasjes J, Richel DJ, Zoetekouw L, Van Lenthe H, De Abreu RA, Maring JG, Vreken P, van Gennip AH (2000) Clinical implications of dihydropyrimidine dehydrogenase (DPD) deficiency in patients with severe 5-fluorouracil-associated toxicity: identification of new mutations in the DPD gene. Clin Cancer Res 6:4705–4712
    PubMed Google Scholar
27. Raida M, Schwabe W, Hausler P, van Kuilenburg AB, van Gennip AH, Behnke D, Hoffken K (2001) Prevalence of a common point mutation in the dihydropyrimidine dehydrogenase (DPD) gene within the 5′-splice donor site of intron 14 in patients with severe 5-fluorouracil (5-FU)-related toxicity compared with controls. Clin Cancer Res 7:2832–2839
    PubMed Google Scholar
28. O’Connell MJ, Mailliard JA, Macdonald JS, Haller DG, Mayer RJ, Wieland HS (1997) Controlled trial of fluorouracil and low-dose leucovorin given for 6 months as postoperative adjuvant therapy for colon cancer. J Clin Oncol 15:246–250
    PubMed Google Scholar
29. Moertel CG, Fleming TR, Macdonald JS, Haller DG, Laurie JA, Goodman PJ, Ungerleider JS, Emerson WA, Tormey DC, Glick JH et al (1990) Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma. N Engl J Med 322:352–358
    PubMed Google Scholar
30. Ardalan B, Chua L, Tian EM, Reddy R, Sridhar K, Benedetto P, Richman S, Legaspi A, Waldman S, Morrell L et al (1991) A phase II study of weekly 24-hour infusion with high-dose fluorouracil with leucovorin in colorectal carcinoma. J Clin Oncol 9:625–630
    PubMed Google Scholar
31. SAKK (1995) Long-term results of single course of adjuvant intraportal chemotherapy for colorectal cancer. Swiss Group for Clinical Cancer Research (SAKK). Lancet 345:349–353
    Google Scholar
32. Lassmann S, Bauer M, Soong R, Schreglmann J, Tabiti K, Nährig J, Rüger R, Höfler H, Werner M (2002) Quantification of CK20 gene and protein expression in colorectal cancer by RT-PCR and immunohistochemistry reveals inter- and intratumour heterogeneity. J Pathol 198:198–206
    Article PubMed Google Scholar
33. Sanguedolce R, Vultaggio G, Sangueldolce F, Modica G, Volsi FL, Diana G, Guerreio G, Bellanca L, Rausa L (1998) The role of thymidylate synthase levels in the prognosis and the treatment of patients with colorectal cancer. Anticancer Res 18:1515–1520
    PubMed Google Scholar
34. Paradiso A, Simone G, Petroni S, Leone B, Vallejo C, Lacava J, Romero A, Machiavelli M, De Lena M, Allegra CJ, Johnston PG (2000) Thymidilate synthase and p53 primary tumour expression as predictive factors for advanced colorectal cancer patients. Br J Cancer 82:560–567
    Article PubMed Google Scholar
35. Findlay MP, Cunningham D, Morgan G, Clinton S, Hardcastle A, Aherne GW (1997) Lack of correlation between thymidylate synthase levels in primary colorectal tumours and subsequent response to chemotherapy. Br J Cancer 75:903–909
    PubMed Google Scholar
36. Allegra CJ, Parr AL, Wold LE, Mahoney MR, Sargent DJ, Johnston P, Klein P, Behan K, O’Connell M, Levitt R, Kugler JW, Tirona MT, Goldberg RM (2002) Investigation of the prognostic and predictive value of thymidylate synthase, p53, and Ki-67 in patients with locally advanced colon cancer. J Clin Oncol 20:1735–1743
    Article PubMed Google Scholar
37. Specht K, Richter T, Muller U, Walch A, Werner M, Hofler H (2001) Quantitative gene expression analysis in microdissected archival formalin-fixed and paraffin-embedded tumor tissue. Am J Pathol 158:419–429
    PubMed Google Scholar
38. Fox SB, Moghaddam A, Westwood M, Turley H, Bicknell R, Gatter KC, Harris AL (1995) Platelet-derived endothelial cell growth factor/thymidine phosphorylase expression in normal tissues: an immunohistochemical study. J Pathol 176:183–190
    Article PubMed Google Scholar
39. Guimbaud R, Guichard S, Dusseau C, Bertrand V, Aparicio T, Lochon I, Chatelut E, Couturier D, Bugat R, Chaussade S, Canal P (2000) Dihydropyrimidine dehydrogenase activity in normal, inflammatory and tumour tissues of colon and liver in humans. Cancer Chemother Pharmacol 45:477–482
    Article PubMed Google Scholar
40. Johnston SJ, Ridge SA, Cassidy J, McLeod HL (1999) Regulation of dihydropyrimidine dehydrogenase in colorectal cancer. Clin Cancer Res 5:2566–2570
    PubMed Google Scholar
41. Miyamoto S, Ochiai A, Boku N, Ohtsu A, Tahara M, Yoshida S, Okabe H, Takechi T, Fukushima M (2001) Discrepancies between the gene expression, protein expression, and enzymatic activity of thymidylate synthase and dihydropyrimidine dehydrogenase in human gastrointestinal cancers and adjacent normal mucosa. Int J Oncol 18:705–713
    PubMed Google Scholar
42. Takebayashi Y, Yamada K, Miyadera K, Sumizawa T, Furukawaw T, Kinoshita F, Aoiki D, Okumura H, Yamada Y, Akiyama S, Aikou T (1996) The activity and expression of thymidine phosphorylase in human solid tumours. Eur J Cancer 32A:1227–1232
    Article PubMed Google Scholar
43. Miwa M, Ura M, Nishida M, Sawada N, Ishikawa T, Mori K, Shimm N, Umeda I, Ishitsuka H (1998) Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue. Eur J Cancer 34:1274–1281
    Article PubMed Google Scholar
44. Mori K, Hasegawa M, Nishida M, Toma H, Fukuda M, Kubota T, Nagasue N, Yamana H, Hirakawa YS, Chung K, Ikeda T, Takasaki K, Oka M, Kameyama M et al (2000) Expression levels of thymidine phosphorylase and dihydropyrimidine dehydrogenase in various human tumor tissues. Int J Oncol 17:33–38
    PubMed Google Scholar
45. Mimori K, Matsuyama A, Yoshinaga K, Yamashita K, Masuda T, Inoue H, Ueo H, Mori M (2002) Localization of thymidine phosphorylase expression in colorectal carcinoma tissues by in situ RT-PCR assay. Oncology 62:327–332
    Article PubMed Google Scholar
46. Pestalozzi BC, McGinn CJ, Kinsella TJ, Drake JC, Glennon MC, Allegra CJ, Johnston PG (1995) Increased thymidylate synthase protein levels are principally associated with proliferation but not cell cycle phase in asynchronous human cancer cells. Br J Cancer 71:1151–1157
    PubMed Google Scholar
47. Backus HH, Van Groeningen CJ, Vos W, Dukers DF, Bloemena E, Wouters D, Pinedo HM, Peters GJ (2002) Differential expression of cell cycle and apoptosis related proteins in colorectal mucosa, primary colon tumours, and liver metastases. J Clin Pathol 55:206–211
    PubMed Google Scholar
48. Lincoln DW II, Hrushesky WJ, Wood PA (2000) Circadian organization of thymidylate synthase activity in normal tissues: a possible basis for 5-fluorouracil chronotherapeutic advantage. Int J Cancer 88:479–485
    Article PubMed Google Scholar
49. Ishikawa T, Sekiguchi F, Fukase Y, Sawada N, Ishitsuka H (1998) Positive correlation between the efficacy of capecitabine and doxifluridine and the ratio of thymidine phosphorylase to dihydropyrimidine dehydrogenase activities in tumors in human cancer xenografts. Cancer Res 58:685–690
    PubMed Google Scholar

Download references